In response to criticism of its arrangement with the US Army to produce a Zika virus vaccine, a Sanofi executive maintained the company is not pursuing the project based on “commercial return” and intends to price the vaccine in order to “facilitate access” in the interest of public health.
The reassurances were offered in a May 22 letter sent to a House Energy and Commerce subcommittee amid mounting concerns the Army will offer Sanofi an exclusive license on two patents without receiving a commitment that a vaccine will be affordable for Americans whose tax dollars funded the discovery.
About the Author Reprints
